Xeris Pharmaceuticals Receives U.S. Patent for Injection of Ultra-Concentrated Drugs and Biologics

Published: Mar 20, 2012

Austin, TX, March 20, 2012 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that is has been granted U.S. Patent No. 8,110,209, "Intracutaneous Injection," modernizing drug and biologic injections by making them easy-to-use and patient-friendly. The new technology will enable biologics that are typically given as aqueous injections to be reformulated into a biocompatible, ultra-concentrated, non-aqueous suspension. Different from their predecessors, these suspensions can be directly injected without reconstitution saving time during medical emergencies related to Type 1 diabetes and epilepsy among other diseases.

Back to news